We recommend that all patients considered potential candidates for future CAR T-cell therapy are assessed for cBTKi failure risk and discussed with a CAR T-cell centre at first relapse according to that risk. Mantle cell lymphoma, BTKi failure, CAR T-cell therapy, cellular therapy in mantle cell lymphoma, Tecartus 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease Keywords: mantle cell lymphoma; BTKi failure; CAR T-cell therapy; cellular therapy in mantle cell lymphoma; Tecartus EN mantle cell lymphoma BTKi failure CAR T-cell therapy cellular therapy in mantle cell lymphoma Tecartus 40 44 5 09/28/22 20221001 NES 221001 The BSH guideline for the management of mantle cell lymphoma (MCL)1 is under review. [Extracted from the article]